James Ahlers - RenovoRx Chief Officer
| RNXT Stock | USD 1.27 0.01 0.79% |
Insider
James Ahlers is Chief Officer of RenovoRx
| Age | 60 |
| Address | 4546 El Camino Real, Los Altos, CA, United States, 94022 |
| Phone | 650 284 4433 |
| Web | https://renovorx.com |
RenovoRx Management Efficiency
The company has return on total asset (ROA) of (0.7008) % which means that it has lost $0.7008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5512) %, meaning that it created substantial loss on money invested by shareholders. RenovoRx's management efficiency ratios could be used to measure how well RenovoRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.58 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (6.63). At this time, RenovoRx's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 4.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| James CPA | Longeveron LLC | 58 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| David Hovland | Eledon Pharmaceuticals | N/A | |
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 40 | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| Tomasz George | Virax Biolabs Group | 40 | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Jeffrey Ecsedy | Ikena Oncology | 54 | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Mark Peikin | Adial Pharmaceuticals | N/A | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 46 | |
| DSc FRCPsych | Adial Pharmaceuticals | 62 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| MBA MD | Monopar Therapeutics | 38 | |
| KwanHong MD | Longeveron LLC | 57 | |
| MBA MD | Ikena Oncology | 59 | |
| Alfredo Castro | Ikena Oncology | N/A | |
Management Performance
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.7 |
RenovoRx Leadership Team
Elected by the shareholders, the RenovoRx's board of directors comprises two types of representatives: RenovoRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RenovoRx. The board's role is to monitor RenovoRx's management team and ensure that shareholders' interests are well served. RenovoRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RenovoRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald CPA, VP Controller | ||
| James Ahlers, Chief Officer | ||
| Leesa Gentry, Senior Operations | ||
| Angela Nelms, Chief Officer | ||
| Ryan Witt, Senior Partnerships | ||
| Ramtin MD, Chairman Founder | ||
| CGMA CPA, Controller VP | ||
| Shaun Bagai, Secretary CEO |
RenovoRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RenovoRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | 20.92 M | ||||
| Shares Outstanding | 24 M | ||||
| Shares Owned By Insiders | 1.90 % | ||||
| Shares Owned By Institutions | 8.18 % | ||||
| Number Of Shares Shorted | 86.95 K | ||||
| Price To Book | 4.31 X | ||||
| EBITDA | (11.4 M) | ||||
| Net Income | (10.23 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.